In 2015, i3 Pharmaceuticals acquired a 150,000 sqft facility in Warminster, PA.

After substantial capital investment, the facility was commissioned in 2017. As a result of our first ANDA file in 2018, i3 Pharmaceuticals passed its first Prior Approval and GMP inspection.

More than half of the site is dedicated to state-of-the-art pharmaceutical development and manufacturing processes including research and analytical laboratories, pilot and commercial manufacturing plants and warehousing.